Profound Medical Corp (PRN) - Net Assets
Based on the latest financial reports, Profound Medical Corp (PRN) has net assets worth CA$91.06 Million CAD (≈ $65.87 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$193.10 Million ≈ $139.69 Million USD) and total liabilities (CA$102.04 Million ≈ $73.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PRN asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$91.06 Million |
| % of Total Assets | 47.16% |
| Annual Growth Rate | 46.47% |
| 5-Year Change | 12.96% |
| 10-Year Change | 725.01% |
| Growth Volatility | 234.03 |
Profound Medical Corp - Net Assets Trend (2014–2025)
This chart illustrates how Profound Medical Corp's net assets have evolved over time, based on quarterly financial data. Also explore how large is Profound Medical Corp's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Profound Medical Corp (2014–2025)
The table below shows the annual net assets of Profound Medical Corp from 2014 to 2025. For live valuation and market cap data, see Profound Medical Corp (PRN) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CA$91.06 Million ≈ $65.87 Million |
+50.71% |
| 2024-12-31 | CA$60.42 Million ≈ $43.71 Million |
+93.78% |
| 2023-12-31 | CA$31.18 Million ≈ $22.56 Million |
-40.04% |
| 2022-12-31 | CA$52.00 Million ≈ $37.62 Million |
-35.49% |
| 2021-12-31 | CA$80.62 Million ≈ $58.32 Million |
-17.19% |
| 2020-12-31 | CA$97.35 Million ≈ $70.42 Million |
+581.32% |
| 2019-12-31 | CA$14.29 Million ≈ $10.34 Million |
-26.91% |
| 2018-12-31 | CA$19.55 Million ≈ $14.14 Million |
+73.84% |
| 2017-12-31 | CA$11.25 Million ≈ $8.13 Million |
+1.88% |
| 2016-12-31 | CA$11.04 Million ≈ $7.98 Million |
+9.70% |
| 2015-12-31 | CA$10.06 Million ≈ $7.28 Million |
+635.46% |
| 2014-12-31 | CA$1.37 Million ≈ $989.71K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Profound Medical Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39396645475.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CA$443.90 Million | 487.46% |
| Other Comprehensive Income | CA$6.89 Million | 7.56% |
| Other Components | CA$34.69 Million | 38.10% |
| Total Equity | CA$91.06 Million | 100.00% |
Profound Medical Corp Competitors by Market Cap
The table below lists competitors of Profound Medical Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SIM Acquisition Corp. I Class A Ordinary Shares
NASDAQ:SIMA
|
$246.56 Million |
|
Polyram Plastic Industries Ltd
TA:POLP
|
$246.74 Million |
|
IAR Systems Group AB (publ)
ST:IAR-B
|
$246.77 Million |
|
Thoresen Thai Agencies Public Company Limited
BK:TTA-R
|
$246.80 Million |
|
Kogan.com Ltd
AU:KGN
|
$246.49 Million |
|
Humedix Co Ltd
KQ:200670
|
$246.43 Million |
|
Metro Mining Limited
F:6ME
|
$246.37 Million |
|
Luca Mining Corp.
V:LUCA
|
$246.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Profound Medical Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 60,422,000 to 91,064,405, a change of 30,642,405 (50.7%).
- Net loss of 59,482,574 reduced equity.
- Other comprehensive income increased equity by 4,146,018.
- Other factors increased equity by 85,978,961.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-59.48 Million | -65.32% |
| Other Comprehensive Income | CA$4.15 Million | +4.55% |
| Other Changes | CA$85.98 Million | +94.42% |
| Total Change | CA$- | 50.71% |
Book Value vs Market Value Analysis
This analysis compares Profound Medical Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.49x to 3.12x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CA$6.31 | CA$9.39 | x |
| 2015-12-31 | CA$4.25 | CA$9.39 | x |
| 2016-12-31 | CA$2.66 | CA$9.39 | x |
| 2017-12-31 | CA$1.83 | CA$9.39 | x |
| 2018-12-31 | CA$1.95 | CA$9.39 | x |
| 2019-12-31 | CA$1.29 | CA$9.39 | x |
| 2020-12-31 | CA$5.63 | CA$9.39 | x |
| 2021-12-31 | CA$3.94 | CA$9.39 | x |
| 2022-12-31 | CA$2.50 | CA$9.39 | x |
| 2023-12-31 | CA$1.47 | CA$9.39 | x |
| 2024-12-31 | CA$2.44 | CA$9.39 | x |
| 2025-12-31 | CA$3.01 | CA$9.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Profound Medical Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -65.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -264.44%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 2.12x
- Recent ROE (-65.32%) is above the historical average (-122.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -599.66% | 0.00% | 0.00x | 1.08x | CA$-8.34 Million |
| 2015 | -117.28% | 0.00% | 0.00x | 1.52x | CA$-12.81 Million |
| 2016 | -110.05% | 0.00% | 0.00x | 1.60x | CA$-13.25 Million |
| 2017 | -133.10% | -383.77% | 0.18x | 1.97x | CA$-16.09 Million |
| 2018 | -77.98% | -797.88% | 0.06x | 1.75x | CA$-17.20 Million |
| 2019 | -108.19% | -365.30% | 0.14x | 2.09x | CA$-16.89 Million |
| 2020 | -22.21% | -296.03% | 0.07x | 1.07x | CA$-31.36 Million |
| 2021 | -38.08% | -446.66% | 0.08x | 1.08x | CA$-38.76 Million |
| 2022 | -55.13% | -429.11% | 0.10x | 1.24x | CA$-33.87 Million |
| 2023 | -91.63% | -396.85% | 0.16x | 1.41x | CA$-31.69 Million |
| 2024 | -46.04% | -260.45% | 0.15x | 1.16x | CA$-33.86 Million |
| 2025 | -65.32% | -264.44% | 0.12x | 2.12x | CA$-68.59 Million |
Industry Comparison
This section compares Profound Medical Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,141,530
- Average return on equity (ROE) among peers: -399.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Profound Medical Corp (PRN) | CA$91.06 Million | -599.66% | 1.12x | $246.52 Million |
| Aurora Spine Corp (ASG) | $3.28 Million | -7.07% | 1.18x | $13.55 Million |
| MedX Health Corp (MDX) | $-1.83 Million | 0.00% | 0.00x | $13.05 Million |
| NuGen Medical Devices Inc (NGMD) | $-2.06 Million | 0.00% | 0.00x | $3.41 Million |
| Perimeter Medical Imaging AI Inc (PINK) | $7.42 Million | -225.80% | 0.34x | $31.30 Million |
| Therma Bright Inc (THRM) | $-71.59K | 0.00% | 0.00x | $2.52 Million |
| Theralase Technologies Inc. (TLT) | $1.05 Million | 5.63% | 0.15x | $58.45 Million |
| VentriPoint Diagnostics Ltd (VPT) | $189.71K | -2568.15% | 8.93x | $20.53 Million |
About Profound Medical Corp
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping… Read more